Tonsillectomy plus standard care vs usual care
> 50% increase in SCr · people IgA nephropathy
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
82 questions · 82 findings · 4 reviews
No studies found 12 · 14.6%GRADE not reported 0 · 0%Very low 25 · 30.5%Low 29 · 35.4%Moderate 16 · 19.5%High 0 · 0%
Tonsillectomy plus standard care vs usual care
Proteinuria · people IgA nephropathy
1 finding from 1 review
- no estimate extracted2 studies · 69 participantsLow
Calcineurin inhibitors ± steroids vs alkylating agents ± steroids
Death at final · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes death at final compared with alkylating agents ± steroids (very low certainty).
1 finding from 1 review
- Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome 2021 · Cochrane Headline outcomes onlyRR 0.9 [0.35, 2.34]7 studies · 394 participantsVery low
Calcineurin inhibitors ± steroids vs alkylating agents ± steroids
End‐stage renal disease · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes end‐stage kidney disease at final compared with alkylating agents ± steroids (very low certainty).
1 finding from 1 review
- Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome 2021 · Cochrane Headline outcomes onlyRR 2.4 [0.64, 9.01]5 studies · 293 participantsVery low
Calcineurin inhibitors ± steroids vs alkylating agents ± steroids
Total remission (complete or partial) at final · primary membranous nephropathy in adults with nephrotic syndrome
Calcineurin inhibitors ± steroids showed no clear difference in total remission at final compared with alkylating agents ± steroids (moderate certainty).
1 finding from 1 review
- Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome 2021 · Cochrane Headline outcomes onlyRR 1.01 [0.89, 1.15]10 studies · 529 participantsModerate
Calcineurin inhibitors ± steroids vs alkylating agents ± steroids
Complete remission · primary membranous nephropathy in adults with nephrotic syndrome
Calcineurin inhibitors ± steroids showed no clear difference in complete remission at final compared with alkylating agents ± steroids (low certainty).
1 finding from 1 review
- Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome 2021 · Cochrane Headline outcomes onlyRR 1.15 [0.84, 1.56]10 studies · 533 participantsLow
Calcineurin inhibitors ± steroids vs alkylating agents ± steroids
Relapse · primary membranous nephropathy in adults with nephrotic syndrome
Calcineurin inhibitors ± steroids showed no clear difference in recurrence of disease (relapse) at final compared with alkylating agents ± steroids (low certainty).
1 finding from 1 review
- Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome 2021 · Cochrane Headline outcomes onlyRR 2.13 [0.71, 6.37]6 studies · 295 participantsLow
Calcineurin inhibitors ± steroids vs alkylating agents ± steroids
100% increase in SCr at final · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes 100% increase in SCr at final compared with alkylating agents ± steroids (very low certainty).
1 finding from 1 review
- Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome 2021 · Cochrane Headline outcomes onlyRR 0.7 [0.3, 1.67]2 studies · 132 participantsVery low
Calcineurin inhibitors ± steroids vs alkylating agents ± steroids
Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ temporary or permanent… compared with alkylating agents ± steroids (very low certainty).
1 finding from 1 review
- Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome 2021 · Cochrane Headline outcomes onlyRR 1.43 [0.31, 6.67]3 studies · 151 participantsVery low
Calcineurin inhibitors ± steroids vs alkylating agents ± steroids
Adverse events ‐ infection ( · primary membranous nephropathy in adults with nephrotic syndrome
Calcineurin inhibitors ± steroids showed no clear difference in adverse events ‐ infection ( compared with alkylating agents ± steroids (low certainty).
1 finding from 1 review
- Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome 2021 · Cochrane Headline outcomes onlyRR 0.86 [0.43, 1.71]9 studies · 552 participantsLow
Calcineurin inhibitors ± steroids vs alkylating agents ± steroids
Malignancy · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ malignancy (range 30 to 36 months compared with alkylating agents ± steroids (very low certainty).
1 finding from 1 review
- Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome 2021 · Cochrane Headline outcomes onlyRR 0.18 [0.01, 3.69]2 studies · 127 participantsVery low
Mycophenolate mofetil vs IV cyclophosphamide
Death · patients with induction therapy in lupus nephritis
It is very uncertain whether mycophenolate mofetil (MMF) changes death compared with IV cyclophosphamide (CPA) (very low certainty).
1 finding from 1 review
- Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes onlyRR 1.12 [0.61, 2.06]8 studies · 826 participantsVery low
Mycophenolate mofetil (MMF) + tacrolimus (TAC) vs IV cyclophosphamide
Partial renal remission · Patients with proliferative lupus nephritis
Mycophenolate mofetil (MMF) + tacrolimus (TAC) showed no clear difference in partial renal remission compared with IV cyclophosphamide (CPA) (low certainty).
1 finding from 1 review
- Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes onlyRR 1 [0.78, 1.28]2 studies · 402 participantsLow
Mycophenolate mofetil (MMF) + tacrolimus (TAC) vs IV cyclophosphamide
Stable kidney function · Patients with proliferative lupus nephritis
Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher stable kidney function compared with IV cyclophosphamide (CPA) (low certainty).
1 finding from 1 review
- Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes onlyRR 1.78 [1.4, 2.26]2 studies · 402 participantsLow
Mycophenolate mofetil vs IV cyclophosphamide
ESKD · patients with induction therapy in lupus nephritis
It is very uncertain whether mycophenolate mofetil (MMF) changes ESKD compared with IV cyclophosphamide (CPA) (very low certainty).
1 finding from 1 review
- Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes onlyRR 0.71 [0.27, 1.84]3 studies · 231 participantsVery low
Mycophenolate mofetil vs IV cyclophosphamide
Complete renal remission · patients with induction therapy in lupus nephritis
Mycophenolate mofetil (MMF) showed no clear difference in complete renal remission compared with IV cyclophosphamide (CPA) (low certainty).
1 finding from 1 review
- Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes onlyRR 1.17 [0.97, 1.42]8 studies · 828 participantsLow
Mycophenolate mofetil vs IV cyclophosphamide
Partial renal remission · patients with induction therapy in lupus nephritis
Mycophenolate mofetil (MMF) showed no clear difference in partial renal remission compared with IV cyclophosphamide (CPA) (low certainty).
1 finding from 1 review
- Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes onlyRR 1.02 [0.89, 1.18]9 studies · 868 participantsLow
Mycophenolate mofetil vs IV cyclophosphamide
Ovarian failure · patients with induction therapy in lupus nephritis
It is very uncertain whether mycophenolate mofetil (MMF) changes ovarian failure compared with IV cyclophosphamide (CPA) (very low certainty).
1 finding from 1 review
- Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes onlyRR 0.36 [0.06, 2.18]3 studies · 539 participantsVery low
Mycophenolate mofetil vs IV cyclophosphamide
Major infection · patients with induction therapy in lupus nephritis
Mycophenolate mofetil (MMF) showed no clear difference in major infection compared with IV cyclophosphamide (CPA) (low certainty).
1 finding from 1 review
- Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes onlyRR 1.02 [0.67, 1.54]6 studies · 699 participantsLow
Mycophenolate mofetil vs IV cyclophosphamide
Alopecia · patients with induction therapy in lupus nephritis
Mycophenolate mofetil (MMF) probably leads to lower alopecia compared with IV cyclophosphamide (CPA) (moderate certainty).
1 finding from 1 review
- Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes onlyRR 0.29 [0.19, 0.46]3 studies · 622 participantsModerate